OTCQB: LXXGF | TSX.V: LXG
Future developments, such as molecular diagnostics, could prove to be game-changers, allowing veterinarians to make highly precise diagnoses through analysis of biological signals in genetic code and proteins to fine-tune the treatments needed.
Dr. Jack Regan, CEO and Founder of LexaGene gives an update to BioPub Investment group on January 26, 2021.
Learn more about the MiQLab solution offering in-clinic point-of-care veterinary diagnostic testing in ~2 hours addressing more than 50 percent of companion animal vet visits and increasing satisfaction.
LexaGene’s MiQLab has direct benefits for veterinary clinics. Using LexaGene’s proven point-of-care diagnostics for evidence-based treatment of common bacterial infections found in companion animals may also result in cost savings.
More than ever, vet practices are looking for efficient and cost-effective methodologies to take control of these variables and manage costs.